<DOC>
	<DOCNO>NCT02684071</DOCNO>
	<brief_summary>The purpose research study test experimental treatment method recurrent progressive brain tumor child age 0-22 year . The use methotrexate chemotherapy ( topotecan cyclophosphamide ) experimental study . This mean use together approve U.S. Food Drug Administration usage .</brief_summary>
	<brief_title>Phase II Study Intraventricular Methotrexate Children With Recurrent Progressive Malignant Brain Tumors</brief_title>
	<detailed_description>The purpose research study test experimental treatment method recurrent progressive brain tumor child age 0-22 year . The use methotrexate chemotherapy ( topotecan cyclophosphamide ) experimental study . This mean use together approve U.S. Food Drug Administration usage . This study attempt determine via serial MRI scan methotrexate administration lateral fourth ventricle combination systemic intravenous topotecan cyclophosphamide effective reduce tumor burden brain spine patient recurrent progressive brain tumor , include medulloblastoma , ependymoma , PNET ( Primitive Neuroectodermal Tumor ) , atypical teratoid/rhabdoid tumor ( AT/RT ) , malignant embryonal tumor . In addition , study evaluate toxicity mention experimental treatment two-year progression-free survival survival child recurrent malignant brain tumor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Recurrent progressive supratentorial posterior fossa tumor measurable disease image study brain spine CSF cytology . Tumor histology , include : Medulloblastoma , PNET , embryonal tumor , Atypical teratoid/rhaboid tumor ( AT/RT ) , Ependymoma . Leptomeningeal dissemination previously diagnose CNS tumor . Diagnosis tumor pathology base upon pathology diagnosis previous surgery patient recurrent tumor . Patients must receive prior radiation current recurrence , unless patient le 36 month old diagnosis progress least one upfront chemotherapy regimen case prior radiation require . Patients must life expectancy least 12 week indicate patient 's oncologist and/or neurosurgeon . Lansky Performance status least 50 . Negative pregnancy test . Specific organ function requirement : Central Nervous System , Bone Marrow , renal liver . Patients meet inclusion criterion . Pregnant lactate female patient . Patients currently enrol another experimental treatment protocol . Patients documented allergy chemotherapy agent use study . Patient/Parent refuse study participation . Patient severely somnolent comatose . Unable unwilling commit return followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>medulloblastoma , ependymoma , AT/RT , embryonal</keyword>
</DOC>